UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overall and worst gleason scores are equally good predictors of prostate cancer progression

BMC urology, 2011-10, Vol.11 (1), p.21-21, Article 21

2011

Volltextzugriff (PDF)

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Volltextzugriff (PDF)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

BMC cancer, 2011-08, Vol.11 (1), p.327-327, Article 327

2011

Volltextzugriff (PDF)

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

The New England journal of medicine, 2009-08, Vol.361 (8), p.745-755

2009

Volltextzugriff (PDF)

MicroRNA expression profiling in prostate cancer

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6130-6135

2007

Volltextzugriff (PDF)

Screening and Prostate-Cancer Mortality in a Randomized European Study

The New England journal of medicine, 2009-03, Vol.360 (13), p.1320-1328

2009

Volltextzugriff (PDF)

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

Journal of bone and mineral research, 2011-12, Vol.26 (12), p.2827-2833

2011

Volltextzugriff (PDF)

Prostate-Cancer Mortality at 11 Years of Follow-up

The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

2012

Volltextzugriff (PDF)

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

Acta oncologica, 2023-12, Vol.62 (12), p.1898-1904

2023

Volltextzugriff (PDF)

The Role of Genetic Markers in the Management of Prostate Cancer

European urology, 2012-10, Vol.62 (4), p.577-587

2012

Volltextzugriff (PDF)

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level

European journal of cancer (1990), 2013-03, Vol.49 (4), p.938-945

2013

Volltextzugriff (PDF)

Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer

Cancer research (Chicago, Ill.), 2015-10, Vol.75 (19), p.4026-4031

2015

Volltextzugriff (PDF)

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Cancer epidemiology, biomarkers & prevention, 2007-11, Vol.16 (11), p.2226-2232

2007

Volltextzugriff (PDF)

TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

Clinical cancer research, 2008-06, Vol.14 (11), p.3395-3400

2008

Volltextzugriff (PDF)

Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA)

The Journal of urology, 2019-03, Vol.201 (3), p.486-495

2019

Volltextzugriff (PDF)

MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2

The Prostate, 2015-06, Vol.75 (8), p.798-805

2015

Volltextzugriff (PDF)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

British journal of cancer, 2018-05, Vol.118 (9), p.1248-1254

2018

Volltextzugriff (PDF)

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

The Journal of urology, 2009-12, Vol.182 (6), p.2670-2676

2009

Volltextzugriff (PDF)

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data

European journal of cancer (1990), 2018-04, Vol.93, p.108-118

2018

Volltextzugriff (PDF)

Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study

American journal of epidemiology, 2008-10, Vol.168 (8), p.925-931

2008

Volltextzugriff (PDF)

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen (PSA) concentration in the Finnish prostate cancer screening trial

BJU international, 2013-10, Vol.112 (6), p.735-741

2013

Volltextzugriff (PDF)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer

British journal of cancer, 2016-11, Vol.115 (11), p.1289-1295

2016

Volltextzugriff (PDF)

Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer

European journal of cancer (1990), 2020-05, Vol.130, p.204-210

2020

Volltextzugriff (PDF)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC

British journal of cancer, 2015-09, Vol.113 (7), p.1086-1093

2015

Volltextzugriff (PDF)

5‐Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial

International journal of cancer, 2016-06, Vol.138 (12), p.2820-2828

2016

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overall and worst gleason scores are equally good predictors of prostate cancer progression

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

MicroRNA expression profiling in prostate cancer

Screening and Prostate-Cancer Mortality in a Randomized European Study

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

Prostate-Cancer Mortality at 11 Years of Follow-up

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

The Role of Genetic Markers in the Management of Prostate Cancer

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level

Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA)

MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data

Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen (PSA) concentration in the Finnish prostate cancer screening trial

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer

Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC

5‐Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial

Aktive Filter

Suchergebnisse filtern